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Abstract
Background
The number of patients with diabetes is increasing particularly in Asia-Pacific region. Many
of them are treated with antidiabetics. As the basis of the studies on the benefit and harm of
antidiabetic drugs in the region, the information on patterns of market penetration of new
classes of antidiabetic medications is important in providing context for subsequent
research and analyzing and interpreting results.
Methods
We compared penetration patterns of dipeptidyl peptidase-4 (DPP-4) inhibitors in Taiwan,
Hong Kong, Japan, and the United States. We used the Taiwan National Health Insurance
Research Database, a random sample of the Hong Kong Clinical Data Analysis and Report-
ing System, the Japan Medical Data Center database, and a 5% random sample of the US
Medicare database converted to the Observational Medical Outcomes Partnership’s Com-
mon Data Model to identify new users of oral antidiabetic medications. We standardized
prevalence and incidence rates of medication use by age and sex to those in the 2010 Tai-
wanese population. We compared age, sex, comorbid conditions, and concurrent medica-
tions between new users of DPP-4 inhibitors and biguanides.
Results
Use of DPP-4 inhibitors 1 year after market entry was highest in Japan and lowest in Hong
Kong. New users had more heart failure, hyperlipidemia, and renal failure than biguanide
users in Taiwan, Hong Kong, and the United States while the proportions were similar in
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Japan. In a country with low penetration of DPP-4 inhibitors (eg, Hong Kong), users had dia-
betes with multiple comorbid conditions compared with biguanidine users. In a country with
high penetration (eg, Japan), the proportion of users with comorbid conditions was similar to
that of biguanide users.
Conclusions
We observed a marked difference of the penetration patterns of newly marketed antidia-
betics in different countries in Asia. Those results will provide the basic information useful in
the future studies.
Introduction
According to the International Diabetes Federation, the number of people with diabetes
worldwide will increase from 425 million in 2017 to 629 million in 2045. More than half are in
the Asia-Pacific region [1]. Glucose control is an essential strategy in diabetes management
aimed at the prevention of microvascular complications with modest benefit in lowering the
risk of macrovascular disorders [2]. Antidiabetic medication is used for glucose control when
lifestyle intervention alone is insufficient to control blood glucose at a target level. In the past 2
decades, new classes of antidiabetic medications have been developed and marketed, including
meglitinides [3], thiazolidinediones [4], dipeptidyl peptidase-4 (DPP-4) inhibitors [5], incretin
mimetics [6], and sodium-glucose cotransporter 2 inhibitors [7].
The benefit and harm profiles associated with these new classes of medications may differ
between the West and Asia. For example, the risks of macrovascular disorders and all-cause
mortality differ substantially between patients with diabetes in the West and those in Asia [8].
These differences increase the importance of further study of the safety and effectiveness of
existing and new antidiabetic medications in Asia. To facilitate such studies, information on
patterns of market penetration of new classes of antidiabetic medications and the characteris-
tics of patients who are prescribed new medication classes compared to old ones across coun-
tries is important in providing context for subsequent research and analyzing and interpreting
results.
The Asian Pharmacoepidemiology Network (AsPEN) is a special interest group of the
International Society of Pharmacoepidemiology for developing and advancing multinational
database research in pharmacoepidemiology in the Asia-Pacific region [9]. The Surveillance of
Health Care in Asian Network (SCAN) project is an activity of AsPEN intended to provide
better understanding of the health and health care resource use of the populations covered in
each participating site database in AsPEN [10]. In the current study, we investigated the pene-
tration of DPP-4 inhibitor use in Taiwan (marketed in March 2009), Hong Kong (November
2007), and Japan (December 2009). For reference, we also examined prescribing patterns for
the same medications in the United States (marketed in October 2006).
Materials and methods
Study design
We conducted a descriptive study where the annual prevalence and incidence of the use of
antidiabetics were compared between Taiwan, Hong Kong, Japan and the US with a particular
attention to the use of DPP-4 inhibitors and biguanides.
Penetration of new antidiabetic medications in East Asian countries and the United States
PLOS ONE | https://doi.org/10.1371/journal.pone.0208796 December 12, 2018 2 / 12
that developed canagliflozin for treatment of Type 2
diabetes. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: This work was supported by
a research agreement between Duke University and
Janssen Research & Development, LLC. Among
authors, P Ryan, M Schuemie, and P Stang are
employees of Janssen, a company that developed
canagliflozin for treatment of Type 2 diabetes. This
does not alter our adherence to PLOS ONE policies
on sharing data and material.
Databases
We used data for 1 million patients collected between 2001 and 2010 from the Taiwan National
Health Insurance Research Database (NHIRD) [11]; a random sample of data collected
between 2008 and 2013 from the Hong Kong Clinical Data Analysis and Reporting System
(CDARS) [12]; data collected between 2006 and 2014 from the Japan Medical Data Center
(JMDC) [13]; and data collected between 2006 and 2011 from a 5% random sample of Medi-
care beneficiaries in the United States [14]. The NHIRD, the JMDC, and the Medicare 5%
sample are claims databases, whereas the CDARS is a computerized clinical management sys-
tem (ie, electronic health record). The NHIRD is a representative sample of the entire popula-
tion of Taiwan, in contrast to the CDARS database, which includes inpatient and outpatient
data for all public hospitals managed by the Hong Kong Hospital Authority. The JMDC data-
base consists of corporate health insurance claims and includes data for persons of working
age and their family members in the same household. Because the JMDC database reflects a
working population, persons 65 years or older are not well represented. For example, the ratio
of workers to their family members is 1.08 among those younger than 65 years, whereas the
ratio is 1.02 among those 65 years or older, indicating that approximately half of older benefi-
ciaries are still working and are likely to be healthier than older persons in the overall Japanese
population. The US Medicare database consists mainly of data for persons 65 years or older,
but also includes data for persons younger than 65 years who receive Social Security Disability
Insurance [15] or have been diagnosed with end-stage renal disease.
The 4 databases were converted to the Observational Medical Outcomes Partnership’s
Common Data Model (CDM) [16]. The research coordinating center in the Duke Clinical
Research Institute (Durham, North Carolina, USA) developed analytic SAS program code
based on the Common Data Model for the SCAN project and distributed the code to each
study site. Each site then ran the SAS routine and returned summary results (without individ-
ual-level information) to the coordinating center.
Participants
We identified patients with at least 1 dispensing of an oral antidiabetic medication, including
biguanides, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, thiazolidinediones, and
DPP-4 inhibitors and all patients with type 2 diabetes and compared the prevalence and inci-
dence rates of the use of the major classes of antidiabetic medications. We defined new (inci-
dent) use for each medication class as at least 1 dispensing of antidiabetic medication of a
particular class after 6 months or longer of no dispensing of any medication in the class. We
further classified new use of a medication class as “single” (ie, new use without concurrent use
of another antidiabetic medication), “dual” (ie, new use with concurrent use of 1 other class of
antidiabetic medication, and “multiple” (ie, new use with concurrent use of 2 or more other
classes of antidiabetic medication). For new users, we identified concurrent medications and
comorbid conditions in the 6 months preceding initiation of the antidiabetic medication of
interest. We standardized the prevalence and incidence rates of medication use to the age and
sex of the Taiwan population in 2010. To characterize new users of DPP-4 inhibitors, we com-
pared the patients with new users of biguanides, because biguanides are considered a first-line
medication in most countries.
Analysis
We compared the distributions of age, sex, and other characteristics between new users of
DPP-4 inhibitors and new users of biguanides and estimated the standardized difference [17].
Although the number of patients with type 2 diabetes in the current study differed between
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countries, standardized differences are not sensitive to sample size. Standardized differences of
greater than 0.1 (or smaller than –0.1) are typically considered meaningful [18].
We analyzed the data in 2 age groups—patients younger than 65 years and patients 65 years
or older—because the former group in the Medicare database and the latter group in the
JMDC database are not representative of the general population. However, we combined the 2
age groups where appropriate.
Relevant guidelines
We conducted the study according to the Guidelines for Good Pharmacoepidemiology Prac-
tices (GPP) [19] and reported the study results according to the STROBE guidelines [20].
This study was approved by the institutional review board of the Duke University Health
System and by the Institutional Review Board of National Cheng Kung University Hospital in
Taiwan, the Institutional Review Board of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster in Hong Kong, and the ethics committee of the Tokyo University
Graduate School and Faculty of Medicine in Japan. All of the data of Medicare 5% sample,
NHIRD, CDARS, and JMDC were fully anonymized before we accessed them. No national
regulation and laws in Taiwan, Hong Kong and Japan apply to sending non-individual-level
information abroad.
Results
Table 1 shows the age and sex distributions of patients with type 2 diabetes. The proportions of
patients 65 years or older were 40.5% in Taiwan, 54.9% in Hong Kong, 19.2% in Japan, and
77.2% in the United States.
Fig 1 shows the prevalence of use of 7 classes of antidiabetic medications (ie, biguanides,
sulfonylureas, insulin, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and
DPP-4 inhibitors). The age- and sex-adjusted prevalence of DPP-4 inhibitor vs. biguanidine
per 1000 patients about 1 year after marketing of DPP-4 inhibitors was 3.1 vs 21.8 in Taiwan
(in 2010), 0.2 vs 18.3 in Hong Kong (in 2009), 4.9 vs 5.5 in Japan (in 2011), and 4.4 vs 53.2 in
the United States (in 2008) among patients younger than 65 years (Fig 1A) and 17.5 vs 123.7 in
Taiwan, 0.8 vs 111.6 in Hong Kong, 21.8 vs 20.5 in Japan, and 9.8 vs 93.1 in the United States
among patients 65 years or older (Fig 1B).
Table 1. Age and sex distribution of patients with type 2 diabetes in Taiwan, Hong Kong, Japan, and the United States.
Characteristic Taiwan NHIRD, 2001–2010
(n = 88,042)
Hong Kong CDARS, 2008–2013
(n = 7493)
Japan JMDC, 2006–2014
(n = 69,895)
US Medicare 5%, 2006–2011
(n = 343,166)
Men, No. (%) 43,711 (49.6) 3630 (48.4) 47,689 (68.2) 134,005 (39.0)
Age group, No.
(%)
0–18 y 972 (1.1) 11 (0.1) 797 (1.1) 0
19–34 y 4473 (5.1) 103 (1.4) 3045 (4.4) 3901 (1.1)
35–44 y 8548 (9.7) 319 (4.3) 8900 (12.7) 10,386 (3.0)
45–54 y 18,831 (21.4) 1191 (15.9) 17,449 (25.0) 24,955 (7.3)
55–64 y 19,568 (22.2) 1754 (23.4) 26,315 (37.6) 39,125 (11.4)
65–69 y 18,220 (20.7) 1379 (18.4) 9482 (13.6) 86,623 (25.2)
70–79 y 13,339 (15.2) 1780 (23.8) 3811 (5.5) 105,307 (30.7)
80–89 y 3757 (4.3) 832 (11.1) 89 (0.1) 60,791 (17.7)
> 90 y 334 (0.4) 124 (1.7) 7 (0.01) 12,078 (3.5)
Abbreviations: CDARS, Clinical Data Analysis and Reporting System; JMDC, Japan Medical Data Center; NHIRD, National Health Insurance Research Database.
https://doi.org/10.1371/journal.pone.0208796.t001
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Fig 2 shows the age- and sex-adjusted incidence rates of new use of each of the 7 classes of
antidiabetic medications. The incidence rate of DPP-4 inhibitors vs biguanides per 1000
patient-years was 2.7 vs 4.9 in Taiwan, 0.3 vs 4.0 in Hong Kong, 5.8 vs 2.0 in Japan, and 3.5 vs
14.1 in the United States among patients younger than 65 years (Fig 2A) and 15.6 vs 14.6 in
Taiwan, 1.5 vs 19.0 in Hong Kong, 26.8 vs 7.2 in Japan, and 7.3 vs 18.0 in the United States
among patients 65 or older (Fig 2B).
Table 2 shows the distributions of age, sex, and other characteristics of new users of DPP-4
inhibitors and biguanides across patients of all ages (The distributions of the 2 age groups are
shown separately in S1 and S2 Tables). New users of DPP-4 inhibitors were in general older
Fig 1. Prevalence per 1000 patients of the use of biguanides (●), sulphonyl urea (�), insulin (4), thiazolidinediones (×), alpha-glucosidase inhibitors (�),
meglitinides (■) and dipeptidyl peptidase 4 (DPP-4) inhibitors (▲) in Taiwan, Hong Kong, Japan, and the United States. Panel A shows patients younger than 65
years; Panel B shows patients 65 years or older. � The study population is not representative of the corresponding age group in the general population in the United
States (see text for details). † The study population is not representative of the corresponding age group in the general population in Japan (see text for details).
https://doi.org/10.1371/journal.pone.0208796.g001
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than new users of biguanides; a biguanidine was used as a single medication in more than 50%
of new users of biguanides in Taiwan, Hong Kong, and the United States, but for approxi-
mately 30% in Japan. A DPP-4 inhibitor was used as a single medication in approximately 5%
of new users of DPP-4 inhibitors in Taiwan and Hong Kong, but for 23% in United States and
37% in Japan. The proportion of patients with heart failure, hyperlipidemia, and renal failure
among new users of DPP-4 inhibitors was higher than among new users of biguanides in Tai-
wan, Hong Kong, and the United States (standardized difference> 0.1), but the difference was
not meaningful (standardized difference�0.1) in Japan. Similarly, the proportion of patients
Fig 2. Incidence per 1000 patient-years of the use of biguanides (●), sulphonyl urea (�), insulin (4), thiazolidinediones (×), alpha-glucosidase inhibitors (�),
meglitinides (■) and dipeptidyl peptidase 4 (DPP-4) inhibitors (▲) in Taiwan, Hong Kong, Japan, and the United States. Panel A shows patients younger than 65
years; Panel B shows patients 65 years or older. † The study population is not representative of the corresponding age group in the general population in the United
States (see text for details). # The study population is not representative of the corresponding age group in the general population in Japan (see text for details).
https://doi.org/10.1371/journal.pone.0208796.g002
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Table 2. Characteristics of new users of dipeptidyl peptidase-4 inhibitors and biguanides.
Characteristic Taiwan Hong Kong Japan United States
DPP-4
Inhibitor
(n = 7497)
Biguanide
(n = 48,447)
Std
Diff
DPP-4
Inhibitor
(n = 530)
Biguanide
(n = 2667)
Std
Diff
DPP-4
Inhibitor
(n = 23,597)
Biguanide
(n = 14,004)
Std
Diff
DPP-4
Inhibitor
(n = 33,420)
Biguanide
(n = 76,132)
Std
Diff
Men, No. (%) 3710 (49.5) 24,615 (50.8) –
0.03
249 (47.0) 1361 (51.0) 16,987 (72.0) 9902 (70.7) 12,622 (37.8) 30,220 (39.7)
Age, mean (SD), y 61.7 (12.7) 56.6 (14.6) 0.35 63.8 (12.6) 62.2 (13.1) 0.12 54.3 (9.7) 51.8 (10.5) 0.24 70.9 (11.8) 69.1 (11.9) 0.15
Pattern, No. (%)a
Single use 431 (5.7) 25,501 (52.6) –
0.94
17 (3.2) 1676 (62.8) –
1.19
8663 (36.7) 4118 (29.4) 0.15 7662 (22.9) 48,421 (63.6) –
0.81
Dual use 2508 (33.5) 20,242 (41.8) –
0.17
91 (17.2) 906 (34.0) –
0.36
7594 (32.2) 5267 (37.6) –
0.11
14,389 (43.1) 22,333 (29.3) 0.29
Multiple use 4558 (60.8) 2704 (5.6) 1.64 424 (80.0) 100 (3.7) 2.06 7340 (31.1) 4619 (33.0) –
0.04
11,369 (34.0) 5378 (7.1) 0.75
Concurrent
antidiabetic
medication, No. (%)
Alpha-glucosidase
inhibitor
1285 (17.1) 1616 (3.3) 0.62 34 (6.4) 15 (0.6) 0.47 4354 (18.5) 2691 (19.2) –
0.02
296 (0.9) 169 (0.2) 0.11
Biguanidine 4500 (60.0) — — 455 (85.8) — — 6949 (29.4) — — 14,913 (44.6) — —
DPP-4 inhibitor — 220 (0.5) — — 33 (1.2) — — 4774 (34.1) — — 6240 (8.2) —
Insulin 914 (12.2) 1520 (3.1) 0.45 109 (20.6) 172 (6.4) 0.50 2360 (10.0) 1700 (12.1) –
0.07
5705 (17.1) 8689 (11.4) 0.17
Meglitinide 670 (8.9) 1705 (3.5) 0.27 1 (0.2) 3 (0.1) 0.03 857 (3.6) 591 (4.2) –
0.03
1137 (3.4) 755 (1.0) 0.18
Sulfonylurea 4519 (60.3) 19,423 (40.1) 0.41 406 (76.6) 877 (32.9) 0.89 7020 (29.7) 4235 (30.2) –
0.01
10,678 (32.0) 14,423 (18.9) 0.31
Thiazolidinedione 1319 (17.6) 1440 (3.0) 0.67 29 (5.5) 12 (0.4) 0.45 3646 (15.5) 2003 (14.3) 0.03 6,897 (20.6) 7107 (9.3) 0.34
Comorbid conditions,
No. (%)
Asthma 364 (4.9) 2516 (5.2) –
0.01
1 (0.2) 13 (0.5) –
0.05
2157 (9.1) 1248 (8.9) 0.01 3614 (0.01) 8673 (11.4) –
0.02
Atrial fibrillation 162 (2.2) 641 (1.3) 0.08 10 (1.9) 24 (0.9) 0.10 491 (2.1) 197 (1.4) 0.05 4377 (13.1) 7901 (10.4) 0.09
COPD 230 (3.1) 1831 (3.8) –
0.04
1 (0.2) 20 (0.7) –
0.06
2364 (10.0) 1266 (9.0) 0.08 2261 (6.8) 5308 (7.0) –
0.01
Dementia 178 (2.4) 710 (1.5) 0.07 0 12 (0.4) –
0.07
74 (0.3) 21 (0.1) 0.04 1640 (< 0.1) 3526 (4.6) 0.01
Depression 336 (4.5) 1860 (3.8) 0.04 2 (0.4) 18 (0.7) –
0.04
1204 (5.1) 692 (4.9) 0.01 2323 (7.0) 5794 (7.6) –
0.02
Epilepsy 41 (0.5) 291 (0.6) –
0.01
0 2 (0.1) –
0.04
366 (1.6) 212 (1.5) 0.01 553 (1.7) 1518 (2.0) –
0.02
Heart failure 444 (5.9) 1695 (3.5) 0.13 19 (3.6) 26 (1.0) 0.22 2483 (10.5) 1252 (8.9) 0.05 7167 (< 0.1) 11,014 (14.5) 0.19
Hyperlipidemia 4098 (54.6) 17,484 (36.1) 0.38 29 (5.5) 67 (2.5) 0.18 14,883 (63.1) 8272 (59.1) 0.08 28,203 (84.4) 56,871 (74.7) 0.23
Hypertension 4368 (58.3) 20,877 (43.1) 0.31 58 (10.9) 188 (7.0) 0.15 12,390 (52.5) 6484 (46.3) 0.12 30,112 (90.1) 63,172 (83.0) 0.20
Malignant
neoplasm
436 (5.8) 1998 (4.1) 0.08 7 (1.3) 36 (1.3) 0.00 4945 (21.0) 2680 (19.1) 0.05 4350 (13.0) 8523 (11.2) 0.06
Mood disorder 359 (4.8) 2047 (4.2) 0.03 2 (0.4) 18 (0.7) –
0.04
1281 (5.4) 740 (5.3) 0.00 2817 (8.4) 7423 (9.8) –
0.05
Myocardial
infarction
66 (2.1) 578 (1.2) 0.08 4 (0.8) 14 (0.5) 0.04 1040 (4.4) 536 (3.8) 0.03 813 (2.4) 1409 (1.9) 0.04
Parkinson disease 356 (0.9) 325 (0.7) 0.02 0 5 (0.2) –
0.05
109 (0.5) 48 (0.3) 0.03 470 (1.4) 938 (1.2) 0.02
Pneumonia 54 (4.7) 1867 (3.9) 0.04 9 (1.7) 37 (1.4) 0.03 977 (4.1) 521 (3.7) 0.02 670 (2.0) 1413 (1.9) 0.01
(Continued)
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with concurrent use of beta-blockers, diuretics, and non-statin lipid-lowering drugs was much
higher among new users of DPP-4 inhibitors than among new users of biguanides in Taiwan,
Hong Kong, and United States (standardized difference> 0.1), but the difference was not
meaningful (standardized difference�0.1) in Japan.
Discussion
To our knowledge, ours is the first study to compare the penetration pattern of a new class of
antidiabetic medications between multiple countries in Asia. Previous studies have examined
patterns of medication use over several years in a single country20or in 2 countries [21].
Table 2. (Continued)
Characteristic Taiwan Hong Kong Japan United States
DPP-4
Inhibitor
(n = 7497)
Biguanide
(n = 48,447)
Std
Diff
DPP-4
Inhibitor
(n = 530)
Biguanide
(n = 2667)
Std
Diff
DPP-4
Inhibitor
(n = 23,597)
Biguanide
(n = 14,004)
Std
Diff
DPP-4
Inhibitor
(n = 33,420)
Biguanide
(n = 76,132)
Std
Diff
Renal failure 591 (7.9) 840 (1.7) 0.39 13 (2.5) 11 (0.4) 0.24 352 (1.5) 120 (0.9) 0.05 3228 (9.7) 3138 (4.1) 0.24
Rheumatoid
arthritis
82 (1.1) 424 (0.9) 0.02 0 0 — 713 (3.0) 342 (2.4) 0.04 1199 (3.6) 2581 (3.4) 0.01
Schizophrenia 54 (0.7) 439 (0.9) –
0.02
0 6 (0.2) –
0.05
298 (1.3) 187 (1.3) 0.00 651 (1.9) 2264 (3.0) –
0.07
Concurrent
medications, No. (%)
Anti-arrhythmic 222 (3.0) 1071 (2.2) 0.05 7 (1.3) 9 (0.3) 0.14 3236 (13.7) 1642 (11.7 0.06 2103 (6.3) 3039 (4.0) 0.11
Antidementia 191 (2.5) 861 (1.8) 0.05 4 (0.8) 12 (0.4) 0.06 33 (0.1) 7 (< 0.1) 0.03 1790 (5.4) 3285 (4.3) 0.05
Antidepressant 776 (10.4) 3667 (7.6) 0.10 23 (4.3) 107 (4.0) 0.02 811 (3.4) 517 (3.7 –
0.02
9762 (29.2) 22,169 (29.1) 0.00
Anti-Parkinson 254 (3.4) 1770 (3.7) –
0.02
1 (0.2) 44 (1.6) –
0.12
154 (0.7) 75 (0.5) 0.03 1546 (4.6) 3476 (4.6) 0.00
Antipsychotic 553 (7.4) 3,47 (7.5) 0.00 32 (6.0) 178 (6.7) –
0.03
682 (2.9) 400 (2.9) 0.00 3010 (9.0) 8174 (10.7) –
0.06
Benzodiazepine 1301 (17.4) 7208 (14.9) 0.07 24 (4.5) 107 (4.0) 0.03 2583 (10.9) 1276 (9.1) 0.06 3038 (9.1) 5681 (7.5) 0.06
β-Blocker 2504 (33.4) 11,854 (24.5) 0.20 192 (36.2) 613 (23.0) 0.30 2127 (9.0) 982 (7.0) 0.07 15,455 (46.2) 28,544 (37.5) 0.18
Calcium channel
blocker
3278 (43.7) 14,474 (29.9) 0.30 214 (40.4) 858 (32.2) 0.17 6081 (25.8) 2831 (20.2) 0.13 10,195 (30.5) 18,425 (24.2) 0.14
COPD medication 2511 (33.5) 16,950 (35.0) –
0.03
24 (4.5) 123 (4.6) 0.00 5379 (22.8) 2936 (21.0) 0.04 9308 (27.9) 19,914 (26.2) 0.04
Diuretic 2537 (33.8) 8941 (18.5) 0.38 85 (16.0) 192 (7.2) 0.31 1370 (5.8) 594 (4.2) 0.07 18,300 (54.8) 35,105 (46.1) 0.17
Non-statin lipid-
lowering drug
927 (12.4) 2766 (5.7) 0.27 29 (5.5) 46 (1.7) 0.25 1457 (6.2) 735 (5.2) 0.04 3306 (9.9) 4966 (6.5) 0.13
NSAID 4308 (57.5) 28,906 (59.7) –
0.04
34 (6.4) 266 (10.0) –
0.12
6840 (29.0) 3721 (26.6) 0.05 7069 (21.2) 15,362 (20.2) 0.02
RAS inhibitor 1117 (14.9) 5961 (12.3) 0.08 245 (46.2) 475 (17.8) 0.68 961 (4.1) 479 (3.4) 0.04 15,111 (45.2) 27,833 (36.6) 0.18
Statin 3215 (42.9) 6105 (12.6) 0.81 235 (44.3) 533 (20.0) 0.57 7581 (32.1) 3715 (26.5) 0.12 21,181 (63.4) 36,388 (47.8) 0.31
Vitamin K
antagonist
111 (1.5) 310 (0.6) 0.10 11 (2.1) 31 (1.2) 0.08 377 (1.6) 140 (1.0) 0.05 3029 (9.1) 5696 (7.5) 0.06
Abbreviations: Std Diff: standardized difference; COPD, chronic obstructive pulmonary disease; DPP-4, dipeptidyl peptidase-4; NSAID, nonsteroidal anti-inflammatory
drug; RAS, renin-angiotensin system.
a Single use refers to new use of a DPP-4 inhibitor or biguanidine without concurrent use or initiation of another antidiabetic medication. Dual use refers to new use of a
DPP-4 inhibitor or biguanidine with concurrent use or initiation of 1 other antidiabetic medication. Multiple use refers to new use of a DPP-4 inhibitor or biguanidine
with concurrent use or initiation of 2 or more other antidiabetic medications.
https://doi.org/10.1371/journal.pone.0208796.t002
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In our study of medication prescribing patterns in Taiwan, Hong Kong, Japan, and the
United States approximately 1 year after marketing of DPP-4 inhibitors began in each country,
prevalence and incidence rates of DPP-4 inhibitor use were highest in Japan and lowest in
Hong Kong. The proportions of comorbid heart failure, hyperlipidemia, and renal failure and
the concurrent use of medications to treat those comorbid conditions among new users of
DPP-4 inhibitors were higher than among new users of biguanides in Taiwan, Hong Kong,
and the United States, but the differences were not meaningful in Japan. This finding suggests
that DPP-4 inhibitors may be preferentially prescribed to more medically complex patients
with diabetes except in Japan.
Different penetration patterns of a new class of antidiabetic medications may be, to some
extent, explained by treatment guidelines and institutional and economic constraints on the
use of new medications. In guidelines in the United States [22] and the European Union [2],
metformin is indicated as the preferred initial pharmacological medication for type 2 diabetes.
Guidelines published by the Japan Diabetes Society [23] indicate, “If good control cannot be
achieved with one type of oral hypoglycemic agent, combination therapy with another drug
having a different mode of action should be carried out”; however, no specific guidance is pro-
vided as to the medication preferred first. This may explain in part the high proportion of “sin-
gle” use among new users of DPP-4 inhibitors and the observation that the proportion of
comorbid conditions and concomitant medications was similar between new users of DPP-4
inhibitors and biguanides in Japan. However, in a treatment guideline for nonspecialists first
published in 2010 by a group of Japanese diabetes specialists [24], biguanides are indicated as
first-line therapy, perhaps reflected in our study in the gradual increase in the prevalence of
biguanide use in Japan (Fig 1). In addition, for DPP-4 inhibitors, no institutional or economic
constraint was present in Japan, which may help to explain the rapid penetration of DPP-4
inhibitors.
In Hong Kong and Taiwan, physicians in general follow the guidelines for treatment of dia-
betes in the West. In addition, in Hong Kong, newly marketed medications are not included in
the drug formulary of public hospitals immediately, and medication cost is not covered by the
public health care system at that time. Consequently, we observed low rates of use of DPP-4
inhibitors in early years of approval. Sitagliptin was listed in the public hospital formulary in
November 2009 and since then the drug cost has been covered. Therefore, the use of DPP-4
inhibitors increased gradually. In Taiwan, after the approval by Taiwan FDA, a newly launched
drug is submitted to the Administration of National Health Insurance to obtain its reimburse-
ment price. The listing of a new drug in the hospital formulary is then acceptable usually in
medical centers first followed by other health service providers. Therefore, it takes around 2 to
3 years for a new drug to be accessible nationwide in Taiwan. In addition, physicians in pri-
mary care settings had the following constrains, which may have deterred them from prescrib-
ing sitagliptin (the only DPP-4 inhibitor available in Taiwan between 2001 and 2010): (1)
sitagliptin can be used only when good glucose control has not been achieved by 2 other medi-
cation classes including biguanides, sulfonylureas, alpha-glucosidase inhibitors, and megliti-
nides; (2) it is requested to report the level of HbA1c 3 to 6 months before and after the
initiation of sitagliptin treatment and the reason for its use and the disease history of the
patient.
The drug price and patients’ out-of-pocket expenditure could be also associated with the
difference of the penetration pattern of DPP-4 inhibitors between countries. In Hong Kong
and Taiwan, all the prescription drugs are covered by the insurance (after the drug is included
in the drug formulary) and therefore, the drug price does not directly affect the out-of-pocket
expenditure. In Japan, the legacy of physician dispensing may affect the penetration pattern of
new drugs. The physician dispensing occurs when prescribing and dispensing are not
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separated where physicians obtain physician markup that is in general higher for more expen-
sive drugs [25,26]. As the treatment with sitagliptin, the first DPP-4 inhibitor in Japan was
more expensive (around $50/month for the typical maintenance dose (100 mg/day)) than the
treatment with metformin (around $7/month for the typical maintenance dose (1,500 mg/
day)), the physician markup was higher for sitagliptin than metformin. This difference of
markup could have worked as one of factors leading to the rapid penetration of DPP-4 inhibi-
tors in Japan. However, it was unlikely that the physician markup had the major impact
because the proportion of separation of prescribing and dispensing was attained for more than
60% of drugs dispensed in 2010 when the rapid increase of the prescription of DPP-4 inhibi-
tors began (Fig 2) [27]. In addition, it has been shown that physicians are more responsive to
the patient’s out-of-pocket costs (10 to 30% of the health care cost including medication fee)
than their own profits from markup [25]. Similarly, in one study in the United States, substan-
tial regional variation in the use of incretin based drugs (mainly sitagliptin introduced in 2006)
was observed in Medicare Part D beneficiaries [28]. The regional variation remained even
after adjusted for sociodemographics including an indicator of low-income subsidy, indicating
that the out-of-pocket expenditure in 2009–2010, which was higher in users of incretin based
drugs ($369) than in users of non- incretin based drugs ($151), was probably not an important
factor accounting for the regional variation of the penetration pattern of incretin based drugs
in the United States.
One strength of the current study is the use of the Common Data Model with a single ana-
lytic program developed in the coordinating center. This approach allowed us to retrieve the
data in the same manner in different countries while no individual-level data were released
from the study sites. Another advantage was the use of large databases, though the sizes dif-
fered substantially between countries.
Our study has limitations. First, the databases were not perfectly comparable in terms of
contents or patient populations. For example, 3 databases were claims databases and 1 data-
base was an electronic medical record system. However, we carefully mapped local codes for
medications and conditions to the standard vocabulary in the Common Data Model to mini-
mize loss of comparability due to different coding systems, and we used age- and sex-standard-
ized prevalence and incidence rates for better comparison. Also, it is likely that the way
medications, diagnoses, and other variables were coded differed between countries. To address
this problem, we compared patterns of prevalence, incidence, and the proportion of patients
with various characteristics between new users of DPP-4 inhibitors and biguanides in each
country first and then the pattern of prevalence or incidence in the 7 medication classes or the
difference in the proportions between DPP-4 inhibitors and biguanides was compared
between the 4 countries.
Conclusion
We observed a marked difference in the market penetration patterns of a new class of antidia-
betic medications, taking DPP-4 inhibitors as an example between 3 Asian countries and the
United States. In a country with low penetration (eg, Hong Kong), patients using DPP-4 inhib-
itors tended to have multiple comorbid conditions, whereas in a country with high penetration
(eg, Japan), the proportion of patients with comorbid conditions was similar between new
users of DPP-4 inhibitors and new users of biguanides. Differences in treatment guidelines
and constraints on the use of the new medication class may partly explain those differences.
However, more studies are needed to confirm the reasons for the different penetration pat-
terns and the impact of the different penetration patterns on treatment outcomes of patients
with diabetes.
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